SCHEMBL5046842

SCHEMBL5046842

Cc1c(C(=O)NCC(C)C)cc(-c2csc(-c3ccccc3Cl)n2)n1CC1CCCO1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 3/20 0.43
IDH1 O75874 1/20 0.43
ALDH1A1 P00352 6/20 0.43
TSHR P16473 3/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALOX15 P16050 2/20 0.42
RECQL P46063 2/20 0.42
BLM P54132 2/20 0.42
EIF4E P06730 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CDC25A P30304 1/20 0.42
CDC25B P30305 1/20 0.42
CDC25C P30307 1/20 0.42
DUSP3 P51452 1/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 3/20 0.42
EPHX2 P34913 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5047024 0.89 ALDH1A1 (0.46) TNK2ALDH1A1TSHRMEN1KMT2A
SCHEMBL5043863 0.89 TNK2 (0.42) TNK2IDH1ALDH1A1TSHRMEN1
SCHEMBL5046918 0.89 ALDH1A1 (0.47) TNK2IDH1ALDH1A1TSHRMEN1
SCHEMBL5048625 0.88 HTR2A (0.46) IDH1MEN1KMT2ARAB9ANPC1
SCHEMBL5048548 0.88 CDC25A (0.46) TNK2ALDH1A1TSHRMEN1KMT2A
SCHEMBL5047884 0.84 CDC25A (0.45) IDH1ALDH1A1TSHRMEN1KMT2A
SCHEMBL5039512 0.84 CDC25A (0.61) ALDH1A1TSHRMEN1KMT2ATDP1
SCHEMBL5047650 0.83 KLKB1 (0.45) IDH1ALDH1A1TSHRMEN1KMT2A
SCHEMBL5044314 0.82 IDH1 (0.46) IDH1ALDH1A1TSHRKMT2AEIF4E
SCHEMBL5048649 0.81 IDH1 (0.49) IDH1ALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583762-B1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
US-7135488-B2 Pyrrolyl-thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2006-11-14 US disclosed
EP-1583762-A1 PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-12 EP disclosed
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives HOFFMAN-LA ROCHE INC. 2004-07-29 US disclosed
WO-2004060888-A1 NOVEL CB 1 RECEPTOR INVERSE AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147572-A1 Novel pyrrolyl-thiazole derivatives CNR1, CNR2, NPY1R TNK2 1585/4885IDH1 3182/4885ALDH1A1 959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.